IP Library › Granted Patent US 12,290,563
Granted Patent B2
US 12,290,563 · App. 17/710,116 · Granted May 6, 2025

Production of

Inventors: Jeroen Geurtsen (Vleuten, NL); Marleen Eveline Weerdenburg (Uithoorn, NL); Pieter Jan Burghout (Pijnacker, NL)
Assignee: Janssen Pharmaceuticals, Inc.
A61K39/385A61K39/0258A61K47/646A61P31/04A61P37/04C12N9/1081A61K2039/55583A61K2039/6087A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,563
App. No.
17/710,116
Granted
May 6, 2025
Kind
B2
Abstract

The invention pertains to host cells for producing a bioconjugate of an E. coli O18 antigen polysaccharide conjugated to a carrier protein. The host cells are characterized in that they comprise modified Wzy O-antigen polymerases with specific combinations of amino acid substitutions in one or more of positions 199, 377 and 395 as compared to the wild type Wzy O-antigen polymerase of SEQ ID NO: 1, which modified Wzy O-antigen polymerases improve the yield and glycosylation pattern of the O18 bioconjugates produced by the host cells. The invention further relates to methods wherein the host cells are used to produce a bioconjugate of an E. coli O18 antigen polysaccharide conjugated to a carrier protein, compositions comprising these bioconjugates, including multivalent compositions comprising bioconjugates of additional O antigen polysaccharide-serotypes.

Claims (46)

1. A gram-negative bacterial host cell comprising:

(a) a carrier protein comprising at least one glycosylation consensus sequence;

(b) an E. coli O18 rfb locus; and,

(c) an oligosaccharyltransferase;

wherein the cell comprises a polypeptide having Wzy O-antigen polymerase activity, which polypeptide comprises an amino acid sequence with at least 95% identity with SEQ ID NO: 1, wherein the amino acid sequence comprises:

i) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1;

ii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and valine at a position that corresponds to position 395 in SEQ ID NO: 1;

iii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1;

iv) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and valine at a position that corresponds to position 395 in SEQ ID NO: 1; or

v) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, methionine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1.

2. A host cell according to claim 1 , wherein the polypeptide having Wzy O-antigen polymerase activity comprises the amino acid sequence of SEQ ID NO: 1, except that the amino acid sequence comprises:

i) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1;

ii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and valine at a position that corresponds to position 395 in SEQ ID NO: 1;

iii) threonine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1;

iv) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and valine at a position that corresponds to position 395 in SEQ ID NO: 1; or

v) isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, methionine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1.

3. A host cell according to claim 1 , wherein the polypeptide having Wzy O-antigen polymerase activity comprises isoleucine at a position that corresponds to position 199 in SEQ ID NO: 1, lysine at a position that corresponds to position 377 in SEQ ID NO: 1, and alanine at a position that corresponds to position 395 in SEQ ID NO: 1.

4. A host cell according to claim 1 , wherein a polynucleotide or vector encoding the polypeptide having Wzy O-antigen polymerase activity is integrated into the genome of the host cell.

5. A host cell according to claim 1 , wherein the host cell is an Escherichia coli host cell.

6. A host cell according to claim 5 , wherein the host cell is an E. coli K-12 strain.

7. A host cell according to claim 1 , wherein at least one of:

a) the oligosaccharyl transferase comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 6;

b) the carrier protein comprises SEQ. ID NO. 3; and,

c) the E. coli O18 rfb locus is an rfb locus of an E. coli strain having serotype O18A.

8. A host cell according to claim 1 , wherein the oligosaccharyl transferase comprises the amino acid sequence of SEQ ID NO: 6.

9. A host cell according to claim 1 , wherein the host cell comprises an E. coli O 18 rfb locus with a nucleotide sequence encoding a Wzy O-antigen polymerase that encodes a polypeptide having Wzy O-antigen polymerase activity and having a sequence as defined in claim 1 .

10. A method for producing a bioconjugate of an E. coli O18 antigen polysaccharide conjugated to a carrier protein, the method comprising: culturing a host cell according to any claim 1 to produce the bioconjugate.

11. A method according to claim 10 , further comprising recovery of the bioconjugate.

12. A method according to claim 11 , further comprising formulating the recovered bioconjugate into a pharmaceutical composition.

13. A method according to claim 12 , further comprising adding one or more additional bioconjugates of E. coli O-antigen polysaccharides conjugated to a carrier protein to the pharmaceutical composition to obtain a multivalent bioconjugate composition.

14. A method according to claim 13 , wherein the one or more additional bioconjugates comprise at least one O-antigen polysaccharide selected from the group consisting of E. coli serotypes O1, O2, O4, O6, O8, O15, O16, O25 and O75.

15. A method according to claim 14 , wherein the multivalent bioconjugate composition comprises:

(i) the bioconjugate of an E. coli O18A antigen polysaccharide conjugated to a carrier protein;

(ii) a bioconjugate of an E. coli O1A antigen polysaccharide conjugated to a carrier protein;

(iii) a bioconjugate of an E. coli O2 antigen polysaccharide conjugated to a carrier protein;

(iv) a bioconjugate of an E. coli glucosylated O4 antigen polysaccharide conjugated to a carrier protein;

(v) a bioconjugate of an E. coli O6A antigen polysaccharide conjugated to a carrier protein;

(vi) a bioconjugate of an E. coli O15 antigen polysaccharide conjugated to a carrier protein;

(vii) a bioconjugate of an E. coli O16 antigen polysaccharide conjugated to a carrier protein;

(viii) a bioconjugate of an E. coli O25B antigen polysaccharide conjugated to a carrier protein; and,

(ix) a bioconjugate of an E. coli O75 antigen polysaccharide conjugated to a carrier protein.

16. A method according to claim 15 , wherein the multivalent bioconjugate composition further comprises:

(x) a bioconjugate of an E. coli O8 antigen polysaccharide conjugated to a carrier protein.

17. The method of claim 15 , wherein the carrier protein in each bioconjugate comprises SEQ ID NO: 3.

18. The method of claim 16 , wherein the carrier protein in each bioconjugate comprises SEQ ID NO: 3.

19. The host cell according to claim 6 , wherein the E. coli K-12 strain is W3110.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2022
From: WEERDENBURG, EVELINE MARLEEN; GEURTSEN, JEROEN; BURGHOUT, PIETER JAN
To: JANSSEN VACCINES & PREVENTION B.V.
Reel/Frame 059995/0528 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2022
From: JANSSEN VACCINES & PREVENTION B.V.
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 059995/0579 →
Priority Claims (1)
EP 21166781 · Apr 1, 2021 · regional
Continuity (1)
Related Publication 20220323576A1 · Oct 13, 2022
References Cited (62)
US 4436727A · Ribi · 1984 [cited by applicant]
US 4866034A · Ribi · 1989 [cited by applicant]
US 4877611A · Cantrell · 1989 [cited by applicant]
US 4912094A · Myers · 1990 [cited by applicant]
US 4987237A · Myers · 1991 [cited by applicant]
US 5057540A · Kensil · 1991 [cited by applicant]
US 5191072A · Hasegawa · 1993 [cited by applicant]
US 5593969A · Kamireddy · 1997 [cited by applicant]
US 5750110A · Prieels · 1998 [cited by applicant]
US 6299884B1 · Van Nest · 2001 [cited by applicant]
US 6451325B1 · Van Nest · 2002 [cited by applicant]
US 6491919B2 · Crane · 2002 [cited by applicant]
US 6676958B2 · Gerber · 2004 [cited by applicant]
US 6759241B1 · Hone · 2004 [cited by applicant]
US 7357936B1 · Garcon · 2008 [cited by applicant]
US 8722064B2 · Reed · 2014 [cited by applicant]
US 9017698B2 · Eldridge · 2015 [cited by applicant]
US 9149521B2 · Eldridge · 2015 [cited by applicant]
US 9149522B2 · Eldridge · 2015 [cited by applicant]
US 9415097B2 · Eldridge · 2016 [cited by applicant]
US 9415101B2 · Eldridge · 2016 [cited by applicant]
US 9504743B2 · Eldridge · 2016 [cited by applicant]
US 20100310602A1 · Reed · 2010 [cited by applicant]
US 20110206758A1 · Vandepapeliere · 2011 [cited by applicant]
US 20150056224A1 · Dubensky, Jr. · 2015 [cited by applicant]
US 20160244489A1 · Masignani et al. · 2016 [cited by applicant]
US 20180099038A1 · Tennants · 2018 [cited by applicant]
EP 0399843 · 1990 [cited by applicant]
EP 0671948 · 1995 [cited by applicant]
EP 0761231 · 1997 [cited by applicant]
EP 0971739 · 2000 [cited by applicant]
EP 1126876 · 2001 [cited by applicant]
EP 1194166 · 2002 [cited by applicant]
EP 1385541 · 2004 [cited by applicant]
GB 2220211 · 1990 [cited by applicant]
WO 2001066572A2 · 2001 [cited by applicant]
WO 2006116423 · 2006 [cited by applicant]
WO 2006119987 · 2006 [cited by applicant]
WO 2007109812 · 2007 [cited by applicant]
WO 2020191082A1 · 2020 [cited by applicant]
International Search Report and Written Opinion issued Sep. 23, 2022 in corresponding PCT/IB2022/053013. [cited by applicant]
Debroy, Chitrita, et al., “Detection of O antigens in [cited by applicant]
Faridmoayer, Amirreza, et al., “Functional characterization of bacterial oligossacharyltransferases involved in O-linked protein glycosylation,” Journal of Bacertiology, American Society for Microbiology, vol. 189, No. … [cited by applicant]
Altschul et al. “Basic local alignment search tool,” J. Mol. Biol. (1990) 215(3):403-410. [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs” Nucleic Acids Res. (1997) 25(17):3389-3402. [cited by applicant]
Carter et al., “A structure-function approach to optimizing TLR4 ligands for human vaccines,” Clin Transl Immunology (2016) 5(11):e108 (8 pages). [cited by applicant]
Cross et al., “Safety and immunogenicity of a polyvalent [cited by applicant]
Gregg et al., “Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery,” (2017) 8(3):e00492-00517. [cited by applicant]
Ho et al., “Preclinical laboratory evaluation of a bivalent [cited by applicant]
Lukac et al., “Toxoid of Pseudomonas aeruginosa exotoxin A generated by deletion of an active-site residue,” Infect Immun (1988) 56(12):3095-3098. [cited by applicant]
Poolman et al., “Extraintestinal Pathogenic [cited by applicant]
Raetz et al., “Bacterial endotoxins: extraordinary lipids that activate eucaryotic signal transduction,” J. Bacteriology (1993) 175(18):5745-5753. [cited by applicant]
Raetz et al., “Lipopolysaccharide endotoxins,” Annu Rev Biochem. (2002) 71:635-700. [cited by applicant]
Reed et al., “Key roles of adjuvants in modern vaccines,” Nature Med (2013) 19(12):1597-1608. [cited by applicant]
Reed et al., “The science of vaccine adjuvants: advances in TLR4 ligand adjuvants,” Curr Opin Immunol (2016) 41:85-90. [cited by applicant]
Stoute et al., “A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group,” (1997) 336(2):86-91. [cited by applicant]
Wacker et al., “N-Linked Glycosylation in Campylobacter jejuni and Its Functional Transfer into [cited by applicant]
Wacker et al., “Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems,” Proc. Nat. Acad. Sci. (2006) 103(18):7088-7093. [cited by applicant]
Woodward et al., “In vitro bacterial polysaccharide biosynthesis: defining the functions of Wzy and Wzz,” Nat Chem Biol. (2010) 6(6): 418-423. [cited by applicant]
European Search Report issued Dec. 14, 2021 in European Patent Application No. 21166781.1. [cited by applicant]
Anonymous: “O18ab/O18ac family O-antigen polymerase [ [cited by applicant]
Francesca Micoli, et al., “Glycoconjugate vaccines: current approaches towards faster vaccine design,” Expert Review of Vaccines, vol. 18, No. 9, pp. 881-895, Aug. 31, 2019. [cited by applicant]